LAM Therapeutics Announces Progress of its Clinical Portfolio with FDA Clearance of New Trial in Leukemia and Advancement of Clinical Trial in Lymphoma

Return to News >

Collaboration announced for combination study with atezolizumab in non-Hodgkin B-cell lymphoma

GUILFORD, Conn.—Nov. 30, 2017– LAM Therapeutics (LAM), a 4Catalyzer company, advanced its clinical portfolio with the U.S. Food and Drug Administration (FDA) clearance of LAM’s Investigational New Drug (IND) application for LAM-003 in leukemia patients. LAM-002 has transitioned into Phase 2 […]

2017-12-20T10:54:35+00:00 November 30th, 2017|Categories: News|

Lymphangioleiomyomatosis Overview

Lymphangioleiomyomatosis (LAM) is a rare lung disease found primarily in women and often affects other organs including lymph nodes and kidneys. LAM is caused by inactivating mutations in the tuberous sclerosis complex (TSC) genes (TSC1 and TSC2), resulting in activation of the mammalian target of rapamycin (mTOR) complex 1 (TORC1) signaling network. LAM can occur […]

2017-11-29T23:05:56+00:00 October 19th, 2017|Categories: Science|

LAM Therapeutics Announces Close of $58M Series C Financing and New Clinical Program in Cancer

Return to News >

Strategy and Portfolio Update

GUILFORD, Conn., March 30, 2017 – LAM Therapeutics, a 4Catalyzer company that develops drugs for cancer and rare diseases, announced that it has closed $58M in Series C financing. 4Catalyzer is Connecticut’s premier biotechnology incubator and has raised over a quarter billion dollars to support its current class […]

2017-12-20T10:57:29+00:00 March 30th, 2017|Categories: News|

LAM Therapeutics Closes $40M in Financing and Announces Two Clinical-Stage Programs in Rare Diseases and Cancer

Return to News >

Bringing the total raised for the current class of 4Catalyzer companies to a quarter-billion dollars

GUILFORD, Conn. –Feb. 2, 2016– LAM Therapeutics closed a $40 million financing to accelerate the development of therapeutics for the treatment of rare diseases and cancer. LAM Therapeutics is a 4Catalyzer company. 4Catalyzer is Connecticut’s premier biotechnology […]

2017-12-20T10:57:06+00:00 February 3rd, 2016|Categories: News|

LAM Therapeutics launches operations to develop drugs for rare lung disease, Lymphangioleiomyomatosis (LAM)

Return to News >

Company is first to focus on developing drugs for Lymphangioleiomyomatosis

Guilford, CT – June 6, 2013 – LAM Therapeutics, the first biopharmaceutical company dedicated to identifying and developing drugs for the treatment of Lymphangioleiomyomatosis (LAM), announced today that it has closed a Series A financing with private investors to launch operations. Proceeds […]

2017-12-20T10:56:35+00:00 June 6th, 2013|Categories: News|